Skip to content

Study · Not a test of the peptide alone · 2000

2 results

Long-term orexigenic effects of AgRP-(83---132) involve mechanisms other than melanocortin receptor blockade.

Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van Der Ploeg LH, Woods SC, Seeley RJ

American journal of physiology. Regulatory, integrative and comparative physiology1 Jul 2000Cited by 198 (Europe PMC)

PMID10896863 (opens in a new tab)DOI10.1152/ajpregu.2000.279.1.r47 (opens in a new tab)PepBankPUB-10896863
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, AgRP-(83-132) given at the same time completely blocked the anorectic effect of MTII, consistent with competitive antagonism.

    In plain wordsIn rats, AgRP-(83-132) given together with melanotan II completely blocked its appetite-reducing effect.

    Peptide
    Melanotan II
    Outcome
    Not applicableBlock of the anorectic effect of MTII by simultaneous AgRP-(83-132)
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    AgRP-(83---132) completely blocks the anorectic effect of MTII (MC3/4-R agonist), given simultaneously, consistent with a competitive antagonist action.
    1 context sentence
    Summary · context
    We report herein that doses as low as 10 pmol can have a potent effect on food intake of rats over a 24-h period after intracerebroventricular injection.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 02AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, AgRP-(83-132) given 24 h before MTII did not reverse the anorectic effect of MTII.

    In plain wordsIn rats, AgRP-(83-132) given a day before melanotan II did not reverse its appetite-reducing effect.

    Peptide
    Melanotan II
    Outcome
    No significant changeReversal of the anorectic effect of MTII by AgRP-(83-132) given 24 h earlier
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    However, when given 24 h prior to MTII, AgRP-(83---132) is ineffective at reversing the anorectic effects of the agonist.
    1 context sentence
    Summary · context
    We report herein that doses as low as 10 pmol can have a potent effect on food intake of rats over a 24-h period after intracerebroventricular injection.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.